LONA · LeonaBio, Inc.
$5.67
+0.40 (+7.59%)
At close · Oct 21
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based upon the Company’s current operating plan, it estimates that its $51.1 million of cash, cash equivalents and investments at June 30, 2026 may not be sufficient to fund its operating expenses and capital expenditure requirements through at least the next 12 months which raises substantial doubt as to our ability to continue as a going concern following the date of this Quarterly Report on Form 10-Q.”View the 10-Q filed Aug 14, 2026
Market Cap
$49.65M
Shares
9.42M
Volume · Oct 21
11.77K
Avg daily vol (3M)
187.1K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.67
Open$5.30
Day$5.30–5.75
52W close$2.87–11.68
Avg vol 30d350K
Short int19K · 0.2% float · 1.0d
Short vol35%
Last earningsAug 14, 2026
DataSep 2020–Oct 2026
Filing10-Q · Aug 14
Up next
Next earnings call
Nov 17, 2026
Est · unconfirmed
· in 4 wks
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$141.46M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$51.07M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+506.9%
Year over year · more shares
Price change (1Y)
+43.6%
Trailing year
Short interest
0.2%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−25%
below
Price vs 50-day avg
−12%
below
RSI (14)
50
neutral
MACD trend
Positive
52-week position
32%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−4%
trailing
6-month return
−38%
trailing
YTD return
−25%
this year
Relative strength
−45%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $8 — 200d above 50d
Institutional flow
Accumulating
+10% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.20% of float · ▼ -19.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
44 holders — near 1-yr high, broad support
Squeeze score
31
low risk · 0–100
Fundamentals
EPS growth
+2%
Y/Y
Free cash flow
$-45.8M
Quant / Vol
risk profile
Volatility
120%
annualized · 1-yr
Max drawdown
−75%
past year
ATR
13.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−25%
Bearish
Price vs 50-day avg
−12%
Bearish
RSI (14)
50
Neutral
MACD trend
Positive
Bullish
52-week position
32%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $6 › 200d $8 — 200d above 50d
Institutional flow
Accumulating
+10% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.20% of float · ▼ -19.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
44 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $6 · 32%
Range high $12
vs 200-day avg -25%
vs 50-day avg -12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LONA
this stock
LeonaBio, Inc.
|
$49.65M | -25.1% | — | — | 0.2% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$131.39B | +15.7% | +46.2% | 30.2 | 1.8% |
|
MRNA
Moderna, Inc.
|
$96.65B | +733.5% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.13B | +4.4% | +20.8% | 20.0 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.22B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LONA | +5.2% | -3.7% | -37.7% | +58.8% | -25.1% |
| SPY | +0.5% | +0.7% | +7.6% | +1.4% | +13.4% |
| vs SPY | +4.7% | -4.4% | -45.3% | +57.5% | -38.5% |